Skip to main content
SpringerLink
Log in

Pharmacokinetics of a New Immediate-Release Methadone Tablet Formulation with Decreased In vitro Solubility

  • Short Communication
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Background: A new tablet formulation of methadone was developed with unique physicochemical properties, allowing for decreased solubility in aqueous solutions in in vitro studies. It was unknown whether this newly developed formulation would affect its bioavailability compared with the currently available formulation of methadone.

Objectives: The objective of this study was to further examine the in vitro solubility of the new methadone formulation, and to evaluate and compare the relative bioavailability and pharmacokinetics to the previous reference formulation after a single oral dose administration under fasting conditions.

Methods: In vitro comparative dissolution for the new methadone formulation and the previous reference formulation was conducted. A randomized, single-dose, blinded, two-period, two-sequence, crossover pharmacokinetic study was performed in 24 healthy volunteers under fasting conditions.

Results: The new methadone formulation demonstrated a 30–40% decrease in solubility over 30 minutes compared with the previous reference formulation at the highest dose; all other doses also showed decreased in vitro solubility. The pharmacokinetic parameters determined were: maximum plasma drug concentration (Cmax) of 38.1 ng/mL; time to reach Cmax (tmax) of 2.80 hours; mean area under the plasma concentration-time curve (AUC) from time zero to 72 hours (AUC72) of 1043 ng • h/mL; mean AUC from time zero to infinity (AUC∞) of 1430 ng • h/mL; mean elimination rate constant (ke) of 0.0206 hours-1; and mean elimination half-life (t1/2) of 36.7 hours. These values are statistically equivalent to the previous reference formulation of methadone.

Conclusion: This study provides the first complete set of pharmacokinetic data on a novel methadone formulation. The formulation demonstrates decreased in vitro solubility while providing equivalent plasma methadone levels compared with the previous formulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Table I
Table II

References

  1. Mercadante S, Casuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001; 19: 2898–904

    PubMed  CAS  Google Scholar 

  2. Leppert W. The role of methadone in cancer pain treatment: a review. Int J Clin Pract 2009; 63: 1095–109

    Article  PubMed  CAS  Google Scholar 

  3. Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev 2007; 17: CD003971

  4. Mizoguchi H, Watanabe C, Yonezawa A, et al. New therapy for neuropathic pain. Int Rev Neurobiol 2009; 85: 249–60

    Article  PubMed  CAS  Google Scholar 

  5. Mannino R, Coyne P, Swainey C, et al. Methadone for cancer-related neuropathic pain: a review of the literature. J Opioid Manag 2006; 2: 269–76

    PubMed  Google Scholar 

  6. Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 2009; 10: 1727–40

    Article  PubMed  CAS  Google Scholar 

  7. Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci 2007; 9: 455–70

    PubMed  Google Scholar 

  8. Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996; 9: 365–73

    Article  PubMed  CAS  Google Scholar 

  9. Moody DE, Alburges ME, Parker RJ, et al. The involvement of cytochrome P450 3A4 in the N-demethylation of l-a-acetylmethadol (laam), norlaam, and methadone. Drug Metab Dispos 1997; 25: 1347–53

    PubMed  CAS  Google Scholar 

  10. Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001; 9: 73–83

    Article  PubMed  CAS  Google Scholar 

  11. Wang SC, Ho IK, Tsou HH, et al. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J Clin Psychopharmacol 2011; 31: 463–9

    Article  PubMed  CAS  Google Scholar 

  12. Bunten H, Liang WJ, Pounder D, et al. CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict Biol 2011; 16: 142–4

    Article  PubMed  CAS  Google Scholar 

  13. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliative Med 2002; 5: 127–38

    Article  Google Scholar 

  14. Wolff K, Rostami-Hodjegan A, Shires S, et al. The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol 1997; 44: 325–34

    Article  PubMed  CAS  Google Scholar 

  15. Foster DJ, Somogyi AA, White JM, et al. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol 2004; 57: 742–55

    Article  PubMed  CAS  Google Scholar 

  16. Plummer JL, Gourlay GK, Cherry DA, et al. Estimation of methadone clearance: application in the management of cancer pain. Pain 1988; 33: 313–22

    Article  PubMed  CAS  Google Scholar 

  17. Metadol® (methadone hydrochloride): Canadian Product Monograph. Montreal: Paladin Labs Inc., 2003

  18. Lynch ME. A review of the use of methadone for the treatment of chronic noncancer pain. Pain Res Manage 2005; 10: 133–44

    Google Scholar 

  19. Betancourt AO, Gosselin, PM, Vinson RK. New immediate release formulation for deterring abuse of methadone. Pharmaceutical Development and Technology. Epub 2012 Apr 27 DOI: 10.3109/10837450.2012.680598

  20. United States Pharmacopeia/National Formulary February 1, 2011 [online]. Available from URL: http://www.uspnf.com [Accessed 2011 Apr 18]

  21. Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med 2009; 10: S124–33

    Article  PubMed  Google Scholar 

  22. Raffa RB, Pergolizzi JV. Opioid formulations designed to resist/deter abuse. Drugs 2010; 70: 1657–75

    Article  PubMed  CAS  Google Scholar 

  23. Gourevitch MN, Hartel D, Tenore P, et al. Three oral formulations of methadone: a clinical and pharmacodynamic comparison. J Subst Abuse Treat 1999; 17: 237–41

    Article  PubMed  CAS  Google Scholar 

  24. Dale O, Hoffer C, Sheffels P, et al. Disposition of nasal, intravenous, and oral methadone in healthy volunteers. Clin Pharmacol Ther 2002; 72: 536–45

    Article  PubMed  CAS  Google Scholar 

  25. Inturrisi CE, Verebely K. Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther 1972; 13: 923–30

    PubMed  CAS  Google Scholar 

  26. Kukanich B, Lascelles BD, Aman AM, et al. The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. J Vet Pharmacol Ther 2005; 28: 461–6

    Article  PubMed  CAS  Google Scholar 

  27. Silver JS, Shaffer HJ. Change intolerance to shifts in methadone formulation: a preliminary investigation. J Subst Abuse Treat 1996; 13: 331–9

    Article  PubMed  CAS  Google Scholar 

  28. Steels MD, Hamilton M, McLean PC. The consequences of a change in formulation of methadone prescribed in a drug clinic. Br J Addict 1992; 87: 1549–54

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

R.K. Vinson was responsible for the design and interpretation of the study, and preparation of the manuscript. All work described in this manuscript was funded by Paladin Labs Inc., Montreal, Canada. R.K. Vinson is an employee of Paladin Labs Inc.

Author information

Authors and Affiliations

  1. Paladin Labs Inc., 100 Alexis-Nihon Blvd., Suite 600, St Laurent, Quebec, Canada, H4M 2P2

    Robert K. Vinson

Authors
  1. Robert K. Vinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert K. Vinson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vinson, R.K. Pharmacokinetics of a New Immediate-Release Methadone Tablet Formulation with Decreased In vitro Solubility. Clin Drug Investig 32, 487–495 (2012). https://doi.org/10.2165/11633550-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11633550-000000000-00000

Keywords

Search

Navigation